FARO RAISES $37.3M TO ACCELERATE CLINICAL TRIALS

Faro's platform uses artificial intelligence and data modeling to reduce the time and complexity of clinical trials. The company targets a critical bottleneck in drug development—lengthy trial timelines that delay patient access to new treatments. Merck Global Health Innovation Fund and S32 jointly led the Series B investment, signaling confidence from both a major pharmaceutical player and institutional capital. The round validates demand for AI-driven solutions in clinical research. Clinical trials remain expensive and time-consuming, often taking years to complete. Faro's tools aim to optimize patient recruitment, data collection, and trial design to accelerate timelines. The company joins a growing number of startups applying machine learning to pharmaceutical and healthcare operations. The funding provides Faro runway to expand its technology platform and customer base within the pharma and biotech sectors.